Compare Bristol-Myers Squibb Co (BMY) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Prudential PLC — how do they compare? Bristol-Myers Squibb Co trades at $63.58 (market cap $129.94B), while Prudential PLC trades at $27.46 (market cap $34.02B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.8× Prudential PLC's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | PUK | |
|---|---|---|
Market Cap | $129.94B | $34.02B |
Sector | Health | Financials |
52-Week High | $65.89 | $33.61 |
52-Week Low | $42.60 | $24.98 |
Enterprise Value | $163.92B | $35.46B |
Dividend Yield | 3.96% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Prudential PLC (PUK) trades at $28.22, down 0.21% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The stock shows strong fundamentals with a P/E of 8.92, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q4 2025, and cash flow from operations reached $3.61B in 2024. However, news of China taxing offshore insurance policies caused a recent sell-off, highlighting regulatory risks.
The outlook for PUK is mixed; solid profitability and low valuation metrics provide upside potential, supported by a 50% analyst buy rating. Key risks include exposure to Chinese regulatory changes and competitive pressures in Asia. Earnings growth and strategic focus on capital-light operations are catalysts, but investor sentiment remains cautious due to near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
